KR20210025075A - Eps를 매개하기 위한 조성물 및 방법 - Google Patents

Eps를 매개하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20210025075A
KR20210025075A KR1020217002442A KR20217002442A KR20210025075A KR 20210025075 A KR20210025075 A KR 20210025075A KR 1020217002442 A KR1020217002442 A KR 1020217002442A KR 20217002442 A KR20217002442 A KR 20217002442A KR 20210025075 A KR20210025075 A KR 20210025075A
Authority
KR
South Korea
Prior art keywords
biofilm
dna
agent
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217002442A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 데이비드 굿맨
로렌 오프렘칵 바칼레츠
Original Assignee
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 filed Critical 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈
Publication of KR20210025075A publication Critical patent/KR20210025075A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217002442A 2018-06-29 2019-06-28 Eps를 매개하기 위한 조성물 및 방법 Withdrawn KR20210025075A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692581P 2018-06-29 2018-06-29
US62/692,581 2018-06-29
PCT/US2019/040008 WO2020006528A2 (en) 2018-06-29 2019-06-28 Compositions and methods for mediating eps

Publications (1)

Publication Number Publication Date
KR20210025075A true KR20210025075A (ko) 2021-03-08

Family

ID=68985235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002442A Withdrawn KR20210025075A (ko) 2018-06-29 2019-06-28 Eps를 매개하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (1) US20210139610A1 (https=)
EP (1) EP3813811A4 (https=)
JP (2) JP7665337B2 (https=)
KR (1) KR20210025075A (https=)
CN (1) CN112672736A (https=)
AU (2) AU2019291944B2 (https=)
BR (1) BR112020026557A2 (https=)
CA (1) CA3104140A1 (https=)
IL (1) IL279459A (https=)
MX (3) MX2020014006A (https=)
SG (1) SG11202013060UA (https=)
WO (1) WO2020006528A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
US20220204600A1 (en) * 2020-12-30 2022-06-30 Trellis Bioscience, Inc. Therapeutic protein formulations comprising anti-dnabii antibodies and uses thereof
WO2022187274A1 (en) * 2021-03-01 2022-09-09 Carlo Ratti Combination therapy for treatment of conditions associated with aging
CN115304656B (zh) * 2022-06-22 2025-01-17 中国人民解放军海军军医大学第一附属医院 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用
CN118541144A (zh) * 2022-12-23 2024-08-23 中国医学科学院基础医学研究所 精胺在预防和治疗炎症性疾病中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
JP5670783B2 (ja) * 2011-03-07 2015-02-18 花王株式会社 バイオフィルムの除去方法
WO2012151555A1 (en) * 2011-05-04 2012-11-08 President And Fellows Of Harvard College Methods and coatings for treating biofilms
RU2694758C2 (ru) * 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
EP2796876A1 (en) * 2013-04-25 2014-10-29 Hasenkam ApS Strip for monitoring analyte concentrations
AU2014268565B2 (en) 2013-05-22 2018-01-18 Curza Global, Llc Compositions and methods comprising a polyamine
US11013858B2 (en) * 2016-01-12 2021-05-25 David S. Goldsmith Nonjacketing side-entry connectors and prosthetic disorder response systems
US20150086561A1 (en) * 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CA2941933A1 (en) 2014-03-13 2015-09-17 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof
SG11201707345VA (en) * 2015-03-12 2017-10-30 Micreos Human Health Bv Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
US9801909B2 (en) * 2015-04-06 2017-10-31 The Penn State Research Foundation Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C
WO2017023863A1 (en) * 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
CA3058813A1 (en) * 2017-04-05 2018-10-11 University Of Utah Research Foundation Compositions and methods comprising a triaryl polyamine

Also Published As

Publication number Publication date
US20210139610A1 (en) 2021-05-13
MX2020014006A (es) 2021-05-27
WO2020006528A3 (en) 2020-02-13
JP7665337B2 (ja) 2025-04-21
CN112672736A (zh) 2021-04-16
AU2019291944B2 (en) 2025-05-29
JP2021529180A (ja) 2021-10-28
MX2025008334A (es) 2025-08-01
SG11202013060UA (en) 2021-01-28
AU2019291944A1 (en) 2021-01-14
WO2020006528A2 (en) 2020-01-02
JP2024138001A (ja) 2024-10-07
IL279459A (en) 2021-01-31
EP3813811A2 (en) 2021-05-05
MX2025008333A (es) 2025-08-01
CA3104140A1 (en) 2020-01-02
EP3813811A4 (en) 2022-08-24
BR112020026557A2 (pt) 2021-04-06
AU2025208543A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
US12239763B2 (en) Peptides and antibodies for the removal of biofilms
JP7665337B2 (ja) Ｅｐｓを媒介するための組成物および方法
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
JP2024060001A (ja) Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
JP2025067928A (ja) バイオフィルム関連障害の処置のための抗体断片
RU2851685C2 (ru) Композиции антител для разрушения биопленок
CN120152740A (zh) 用于破坏非结核分枝杆菌生物膜的抗体组合物和方法
HK1255383B (en) Peptides and antibodies for the removal of biofilms

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid